Abstract
The present study assessed the phenotypic aspects of oral-cavity Candida albicans isolates from 300 HIV-1- positive patients, relating the most commonly investigated virulence factors (enzyme typing and germ-tube formation) to the most common morphotypes. The samples were seeded into specific media for isolation and subsequent identification using the automated Vitek 2 system. The following assays were performed for phenotypic characterization: morphotyping, germ-tube formation and enzyme typing. Out of 300 collected samples, 144 tested positive for yeasts of the Candida genus, 98 (32.7 %) of which were identified as C. albicans. The latter samples were attributed to seven different morphotypes; the three most common morphotypes were 7208 (49 %), 7308 (14.3 %) and 3208 (13.3 %). All of the C. albicans isolate samples formed germ tubes and produced the enzymes proteinase and phospholipase, with an activity classified as intermediate to high. Due to the identification of virulence factors among the analyzed samples, monitoring of HIV-1-positive patients colonized by different morphotypes must be established because these morphotypes are extremely pathogenic and can trigger severe fungal infections.
Keywords: HIV-1, Co-infection, Candida albicans, oral cavity, virulence factors.
Current HIV Research
Title:Virulence Factors of Candida albicans Isolates from the Oral Cavities of HIV-1-Positive Patients
Volume: 11 Issue: 4
Author(s): Tatiany O.A. Menezes, Luciana C.S. Gillet, Sílvio A.F. Menezes, Rosimar N.M. Feitosa, Marluísa O.G. Ishak, Ricardo Ishak, Sílvia H. Marques-da-Silva and Antonio C.R. Vallinoto
Affiliation:
Keywords: HIV-1, Co-infection, Candida albicans, oral cavity, virulence factors.
Abstract: The present study assessed the phenotypic aspects of oral-cavity Candida albicans isolates from 300 HIV-1- positive patients, relating the most commonly investigated virulence factors (enzyme typing and germ-tube formation) to the most common morphotypes. The samples were seeded into specific media for isolation and subsequent identification using the automated Vitek 2 system. The following assays were performed for phenotypic characterization: morphotyping, germ-tube formation and enzyme typing. Out of 300 collected samples, 144 tested positive for yeasts of the Candida genus, 98 (32.7 %) of which were identified as C. albicans. The latter samples were attributed to seven different morphotypes; the three most common morphotypes were 7208 (49 %), 7308 (14.3 %) and 3208 (13.3 %). All of the C. albicans isolate samples formed germ tubes and produced the enzymes proteinase and phospholipase, with an activity classified as intermediate to high. Due to the identification of virulence factors among the analyzed samples, monitoring of HIV-1-positive patients colonized by different morphotypes must be established because these morphotypes are extremely pathogenic and can trigger severe fungal infections.
Export Options
About this article
Cite this article as:
Menezes O.A. Tatiany, Gillet C.S. Luciana, Menezes A.F. Sílvio, Feitosa N.M. Rosimar, Ishak O.G. Marluísa, Ishak Ricardo, Marques-da-Silva H. Sílvia and Vallinoto C.R. Antonio, Virulence Factors of Candida albicans Isolates from the Oral Cavities of HIV-1-Positive Patients, Current HIV Research 2013; 11 (4) . https://dx.doi.org/10.2174/1570162X113119990042
DOI https://dx.doi.org/10.2174/1570162X113119990042 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry New Purine Nucleoside Analogs for Acute Lymphoblastic Leukemia
Clinical Cancer Drugs Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery The Posttranslational Phase of Gene Expression: New Possibilities in Molecular Diagnosis
Current Molecular Medicine Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology Calcium Metabolism & Hypercalcemia in Adults
Current Medicinal Chemistry GABA Puts a Stop to Pain
Current Drug Targets - CNS & Neurological Disorders Lactobacillus Rhamnosus Cell Lysate in the Management of Resistant Childhood Atopic Eczema
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Managed Health Care and Child Mental Health Services: Where Is Horton to Hear the Whos?
Current Pediatric Reviews Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Hereditary Rickets. How Genetic Alterations Explain the Biochemical and Clinical Phenotypes
Endocrine, Metabolic & Immune Disorders - Drug Targets Environmental Pollution and Asthma
Current Respiratory Medicine Reviews Novel Drug Therapies for Fertility Preservation in Men Undergoing Chemotherapy: Clinical Relevance of Protector Agents
Current Medicinal Chemistry Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets Immunity to Tuberculosis and Novel Therapeutic Strategies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)